The 4th Annual Precision Medicine and Immuno-Oncology China Summit 2021 (PMIO China 2021) was successfully held in Zhangjiang, Shanghai recently. Shanghai Medicilon Inc. (Medicilon) and the summit organizer jointly held a symposium on PMIO China 2021 with the theme, “Preclinical Development Strategy of Innovative Drugs Driven by Translational Medicine”.
There were 14 specials reports and 1 round table forum in the summit. The forum focused on industry hot topics such as innovative drug research and development, tumor microenvironment, bispecific antibodies, ADC drugs, CGT process development and quality control, and the industrialization of CAR-T immunotherapy, which could promote the innovation and high-quality development of precision drugs in China!
At the beginning of the forum, Professor Shuangging Peng, CSO of Medicilon, delivered an opening speech. Professor Pang called on the experts in the pharmaceutical field to gather together for resource integration and collaboration and to provide advice and suggestion for solving the problems of preclinical development of innovative drugs to lead the future of healthy China.
Focusing on the “preclinical development strategy of innovative drugs driven by translational medicine”, experts from the field of pharmaceutical research and development shared a wonderful and academic report.
Bingshi Guo, CSO of I-Mab Biopharma, delivered a report titled “Research Progress of Tumor Immune Adenosine Pathway Targets”.
Yizhao Xie, CSO and Head of Research and Early Clinical Development of CStone Pharmaceuticals, gave a report titled “Preclinical to Clinical Development of ADC Drugs targeting ROR1 Target”.
Dengji Zhang, Director of the Pharmacokinetic and Bioanalytical Department of Medicilon, delivered a report titled “Considerations and Basic Practice Strategies for the Development of High Sensitivity Bioanalytical Methods”.
Xiaoning Guo, VP, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals, delivered a report titled “Development of Next Generation Small Molecules Immunotherapy”.
Xingquan Ma, VP of Chemistry Department of Medicilon, delivered a report titled “Advantages and Challenges of PROTAC Technology in Drug Discovery”.
Xiangju Gu, CSO of Laekna Therapeutics, delivered a report titled “Leveraging Targeted Drugs to Enhance Immuno-Tumor Treatment”.
Sixiang Zhou, Vice President of Harbour BioMed, delivered a report titled “New Generation of Fully Human Antibody Technology and HBICE Immune Cell Adapter Technology Based on Heavy Chain Antibody”.
Yi Jin, CSO of GenBase, delivered a report titled “Development of Antibody Drugs for Claudin 6 Targeting Solid Tumors”.
Qing Zhou, Founder & CEO of Escugen, delivered a report titled “Developing Safer and Effective ADC Drugs”.
Linglong Zou, General Manager of Henlius Biotech, delivered a report titled “Bispecific Antibody Biological Analysis”.
Fugen Li, Senior Vice President of Translational Medicine Department of Haihe Biopharma, delivered a report titled “Development of New Drugs under the Guidance of Biomarkers: Difficulties and Breakthroughs”.
Jialiang Wang, Vice President of Transitional Medicine of Cullgen, delivered a report titled “Targeted Protein Degradation-A New Chapter in Small Molecule Drug Development”.
Han Dai, Chief Commercial Officer of Viva Biotech, delivered a report titled “Medicinal Chemistry Beyond Small Molecule Inhibition: New Possibilities Through PROTAC-Induced Protein Degradation”.
Each report has clear topics and different perspectives. Experts in the industry express their opinions and thoughts. The strong academic atmosphere brings new enlightenment to the preclinical development of current innovative drugs, and effectively accelerates the innovation and breakthrough of the new generation of tumor immunotherapy technology to helps China’s future precision drug research and development.
Subsequently, Dr. Fugen Li, Senior Vice President of Translational Medicine Department of Haihe Biopharma; Dr. Xiaoning Guo, VP, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals; Dr. Jialiang Wang, Vice President of Transitional Medicine of Cullgen; and Dr. Han Dai, Chief Commercial Officer of Viva Biotech, participated in the round table forum. As a roundtable host, Dr. Xingquan Ma, VP of Chemistry Department of Medicilon, guided the experts expressing their opinions and thoughts, bursting out the fire of thinking, and igniting the audience’s unlimited imagination of the future “precision medicine” and “tumor immunotherapy”.
2021 is a year of vigorous development in the field of tumor immunotherapy in China, a year of continuous improvement of laws, regulations, and regulatory systems, and a year of rapid growth for Medicilon. Now, Medicilon has established the CAR-T, TCR-T, CAR-NK, Oncolytic Virus, antibodies (monoclonal antibodies, double antibodies, polyclonal antibodies, etc.), siRNA, AAV and other immunotherapy models and methods to empower the research process of innovative therapies.
In the future, Medicilon looks forward to helping more aspiring pharmaceutical companies develop more innovative drugs, promote the rapid development of immunotherapy R&D and innovation in China, and empower the upgrading of life sciences.
Relevant
news
marketing@medicilon.com
